HEERLEN, Netherlands—Royal DSM, a science-based company active in health, nutrition and materials, and Amyris Inc., an industrial bioscience company, enhanced their alliance through the sale of Amyris Brasil Ltda. to DSM and the establishment of a long-term manufacturing partnership for Amyris' high-volume products.
The consideration for Amyris Brasil, which owns and operates the Brotas 1 production facility, and the intellectual property related to farnesene is $58 million, plus an additional value share arrangement over a three-year period amounting to $37.5 million, an aggregate upfront consideration of $96 million, according to a DSM release.
In addition to the consideration upfront, there is potential for a future value share in line with Amyris' business model.
DSM will continue existing supply agreements to Amyris and other parties, and will also supply Amyris with specialty compounds until it realizes its Brotas 2 specialties production facility. Amyris is accelerating the construction of its second facility dedicated to specialty products while maintaining the manufacturing process development and business support capability located in Campinas, Brazil.
The transaction is expected to close in the coming months.